IQV

TentativeAI Memo

IQVIA

As of 2026-05-15/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-15 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators

Action

—

Confidence

medium

Horizon

—

Key catalyst

Expanded buyback authorization adds capital-allocation support • 2026-05-07

Expected move: +5%

Biggest risk

The cautious case is that the print did not fully resolve demand skepticism: revenue guidance was reaffirmed rather than raised, quarterly book-to-bill was 1.04x, leverage remained elevated at 3.62x net debt to adjusted EBITDA, and the simplified 2026 segment model adds an execution and comparability layer [#10-Q-2026-05-05] [#IR-2026-05-05].

Invalidation

Break below $150 or thesis failure.

What would change my mind?

The constructive case is that Q1 showed broad execution rather than a one-off beat: Commercial Solutions grew 11.6%, R&D Solutions grew 6.2%, free cash flow reached $491M, and management raised FY2026 adjusted EPS guidance while reaffirming revenue and EBITDA guidance [#IR-2026-05-05]. With the stock at $170.68 versus a packet median target of $234.19, there is room for recovery if backlog conversion and commercial growth hold.

Research note

Recommendation

—

Confidence

medium

As of

2026-05-15

Base target

$188

p=53%

Bull target

$215

p=22%

Bear target

$150

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

FY2026 EPS guide raise needs confirmation through the rest of 2026
R&D backlog conversion through March 2027 is the main company-specific forward test
The constructive case is that Q1 showed broad execution rather than a one-off beat: Commercial Solutions grew 11.6%, R&D Solutions grew 6.2%, free cash flow reached $491M, and management raised FY2026 adjusted EPS guidance while reaffirming revenue and EBITDA guidance [#IR-2026-05-05].

BearKey bullets

Backlog conversion risk remains central; management highlighted expected 12-month conversion, but the pace at which backlog converts into revenue remains a key operating risk [#10-Q-2026-05-05].
Balance-sheet leverage is still notable, with $15.833B of debt and net leverage of 3.62x as of March 31, 2026 [#10-Q-2026-05-05].
Data access, privacy, cybersecurity, and changing biopharma regulatory requirements remain core operating risks for the platform model [#10-Q-2026-05-05].

WatchKey bullets

Expanded buyback authorization adds capital-allocation support

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $188 (p=53%)

Bull/Bear spread: +21% / -16%

Vs latest close: Bull +21% · Base +5% · Bear -16%

Scenario probabilities

Bull Target: $215 (p=22%)Base Target: $188 (p=53%)Bear Target: $150 (p=25%)

Commentary

The verified primary-source tone is constructive on Q1 execution, EPS guidance, backlog, and repurchases, but forward visibility remains limited because the strongest company-specific test is backlog conversion over the next twelve months rather than an imminent discrete event. Trusted-news reaction was mixed around book-to-bill and demand durability, and no fresh analyst-revision evidence is available in the packet; this should therefore remain a cautious monitoring view.

As of 2026-05-15 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

FY2026 EPS guide raise needs confirmation through the rest of 2026
R&D backlog conversion through March 2027 is the main company-specific forward test

Scenarios

Bull Target (Scenario probability)

$215 / p=22% prob

Base Target (Scenario probability)

$188 / p=53% prob

Bear Target (Scenario probability)

$150 / p=25% prob

Price $178 as of 2026-06-15

Nearest Scenario: Base (∆ 5%)

Targets vs latest close: Bull +21% · Base +5% · Bear -16%

Sentiment & Exposure

News Sentiment (30d)

0.25

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-05-07
Expanded buyback authorization adds capital-allocation support
On May 7, 2026 the board authorized an additional $2B of repurchases, lifting remaining authorization to $3.2B; this is a clear capital-allocation support point, but it is not enough by itself to resolve demand and leverage questions [#8-K-2026-05-07].
Prob 70.00% • Move 3.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

FY2026 EPS guide raise needs confirmation through the rest of 2026
2026-12-31
IQVIA reported Q1 2026 revenue of $4.151B (+8.4% YoY), adjusted EPS of $2.90, Commercial Solutions growth of 11.6%, R&D Solutions growth of 6.2%, and raised full-year 2026 adjusted EPS guidance to $12.65-$12.95 while reaffirming revenue and EBITDA guidance [#10-Q-2026-05-05] [#IR-2026-05-05].
Prob 70% • Move 6% • Priced-in 50%

Long-term Catalysts

Months to a year

R&D backlog conversion through March 2027 is the main company-specific forward test
2027-03-31
IQVIA reported R&D Solutions contracted backlog of $34.2B and said approximately $8.9B should convert to revenue over the next twelve months, up 7.6% year over year; conversion of that backlog, alongside 1.11x trailing-twelve-month book-to-bill, is the key forward evidence needed for a stronger rerating [#10-Q-2026-05-05] [#IR-2026-05-05].
Prob 60% • Move 6% • Priced-in 45%

Risks

Backlog conversion risk remains central; management highlighted expected 12-month conversion, but the pace at which backlog converts into revenue remains a key operating risk [#10-Q-2026-05-05].
Balance-sheet leverage is still notable, with $15.833B of debt and net leverage of 3.62x as of March 31, 2026 [#10-Q-2026-05-05].
Data access, privacy, cybersecurity, and changing biopharma regulatory requirements remain core operating risks for the platform model [#10-Q-2026-05-05].
Most contracts can be terminated on short notice, and large-client delays, cancellations, or losses can pressure bookings, utilization, and margins [#10-Q-2026-05-05].
The January 2026 simplified organizational model may strengthen collaboration and efficiency, but it also makes near-term segment comparisons harder to interpret [#IR-2026-05-05].

Peers

Symbol	Summary
ICLR	ICON is a direct global CRO competitor identified in IQVIA's competitive disclosures; IQVIA's relative case depends on combining CRO scale with commercial data and analytics rather than winning on pure trial-execution growth alone [#10-K-2026-02-17].
FTRE	Fortrea is a direct CRO operating comparator in outsourced clinical development; IQVIA has greater platform breadth and scale, but Fortrea remains relevant for judging sponsor demand, bookings quality, and CRO margin pressure [#10-K-2026-02-17].
TMO	Thermo Fisher is relevant because PPD competes directly with IQVIA in clinical development services; TMO is broader and less pure-play, so it should be used mainly as a large-scale CRO and services benchmark [#10-K-2026-02-17].

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-05-15

AI Stock Memo: IQV - IQVIA - RankAlpha